Addex Therapeutics Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals

Geneva, switzerland, april 19, 2024 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that ceo, tim dyer, will present at the swiss biotech day 2024 conference taking place april 22 - 23, 2024 at the congress center in basel, switzerland.

Top-line data from adx71149 phase 2 epilepsy study expected by mid-may 2024 launched neurosterix with perceptive advisors, raising usd 63 million in series a to accelerate development of preclinical portfolio received chf 5 million upfront and 20% equity in neurosterix, providing cash runway beyond 2026 ad hoc announcement pursuant to art. 53 lr geneva, switzerland, april 18, 2024 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its full-year 2023 financial results for the period ended december 31, 2023 and provided a corporate update.

Geneva, switzerland, april 11, 2024 – addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its full-year 2023 financial results on april 18, 2024. tim dyer, ceo and mikhail kalinichev, head of translational science will provide a business update and a review of the addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 cest (15:00 bst / 10:00 edt / 07:00 pdt) the same day.

Addex receives chf5m and 20% share of neurosterix  perceptive advisors leads $63m investment into neurosterix  addex contributes portfolio of preclinical neuroscience assets and allosteric modulator small molecule discovery technology platform to neurosterix ad hoc announcement pursuant to art. 53 lr geneva, switzerland and new york, usa, april 3, 2024 - addex therapeutics (six and nasdaq: adxn), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, and funds affiliated with perceptive advisors, an investment management firm focused on the life sciences sector, today announced the launch of neurosterix, a company focused on developing allosteric modulators for the treatment of underserved neurological disorders.

Geneva, switzerland, march 14, 2024 – addex therapeutics (six: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that ceo, tim dyer, will present at the bio-europe spring 2024 conference taking place march 18 - 20, 2024 in barcelona, spain. dr. robert lÜtjens, head of discovery – biology, will also be attending this event.

Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland.

Addex Therapeutics Ltd (NASDAQ:ADXN ) Q4 2023 Earnings Conference Call April 18, 2024 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Joanne Lee - Maxim Group Raghuram Selvaraju - H.C. Wainwright & Co. Michael Okunewitch - Maxim Group Operator Good day and thank you for standing by.

Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.

Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Bio-Europe Spring 2024 conference taking place March 18 - 20, 2024 in Barcelona, Spain. Dr. Robert Lütjens, Head of Discovery – Biology, will also be attending this event.

Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 10-12, 2024.

CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will present at Biotech Showcase being held in San Francisco, January 8-10, 2024. In his presentation, scheduled for Monday January 8, 2024 at 4:30 PM PT (01:30 AM CET), Mr Dyer will provide a corporate update and discuss recent advances from Addex's CNS pipeline, including:  ADX71149 in Phase 2 for epilepsy with Janssen Pharmaceuticals, Inc. Dipraglurant in post-stroke recovery GABAB PAM Indivior strategic partnership for substance use disorders M4 PAM schizophrenia program GABAB PAM cough program mGlu2NAM cognition program Presentation Details: Date: Monday, January 08 2024Time: 4:30PMTrack: Yosemite A (Ballroom Level) Mr Dyer will be available for one-on-one meetings throughout the conference.

Addex Therapeutics Ltd. (NASDAQ:ADXN ) Q3 2023 Earnings Conference Call November 29, 2023 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Robert Lutjens - Head of Discovery-Biology Mikhail Kalinichev - Head of Translational Science Conference Call Participants Operator Good day and thank you for standing by.

Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that that it will issue its Third Quarter 2023 Financial Results on November 29, 2023. Tim Dyer, CEO , Robert Lütjens, Head of Discovery – Biology and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST) the same day.

Geneva, Switzerland, September 6 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will be attending the H.C. Wainwright 25th Annual Global Investment Conference (September 11 – 13, 2023) in New York.

Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2023 Results Conference Call August 10, 2023 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Robert Lutjens - Head of Discovery-Biology Mikhail Kalinichev - Head of Transition Science Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright Operator Good day and thank you for standing by.